# Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC

> **NCT03712969** · PHASE4 · COMPLETED · sponsor: **West China Hospital** · enrollment: 527 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Chemotherapy, Adjuvant

## Interventions

- **DRUG:** Shenlingcao Oral Liquid

## Key facts

- **NCT ID:** NCT03712969
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-05
- **Primary completion:** 2022-03-14
- **Final completion:** 2023-05-04
- **Target enrollment:** 527 (ACTUAL)
- **Last updated:** 2024-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03712969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03712969, "Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03712969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*